Eskayef (Now Known ASmithkline Beecham Pharmaceutical(India) Ltd. Etc. vs Commissioner Of Income Tax

Introduction

The Supreme Court of India, in the case of Eskayef (Now Known as SmithKline Beecham Pharmaceuticals (India) Ltd.) vs. Commissioner of Income Tax (2000) 245 ITR 116 (SC), delivered a pivotal judgment concerning the deductibility of certain business expenditures under the Income Tax Act, 1961. This case commentary analyzes the Court’s ruling on two critical issues: the admissibility of surtax liability as a deduction, and the treatment of expenditure on physician’s samples under Section 37(3A) of the Act. The decision, which favored the Revenue, has significant implications for pharmaceutical companies and other industries where promotional activities are indirect. The Supreme Court clarified that the distribution of free drug samples to doctors constitutes ‘publicity and sales promotion,’ thereby subjecting such expenditure to statutory restrictions. This analysis delves into the facts, legal reasoning, and the broader impact of the judgment, ensuring all conclusions are strictly derived from the provided source text.

Facts of the Case

The appeals before the Supreme Court pertained to the Assessment Year 1980-81 and involved two sets of issues. The first issue, common to all appeals, was whether the liability to pay surtax was an admissible deduction in computing total income. The second, more contentious issue, arose in Civil Appeal Nos. 4545 to 4547 of 1996 and concerned the expenditure incurred by the assessee, a pharmaceutical company, on distributing physician’s samples of prescription drugs to medical practitioners. The assessee argued that this expenditure was not in the nature of advertisement, publicity, or sales promotion, and thus fell under the general deduction provision of Section 37(1) of the IT Act, without being subject to the restrictions of Section 37(3A). The Income Tax Appellate Tribunal (ITAT) and the Karnataka High Court had previously ruled against the assessee, holding that such distribution was indeed a form of sales promotion. The High Court, in its earlier judgment in Smith Kline and French (India) Ltd. vs. CIT (1992) 193 ITR 582 (Kar), had reasoned that for prescription drugs, the medical profession is the primary target for promotion, and free samples serve to create a market and goodwill. The assessee appealed to the Supreme Court, challenging this interpretation.

Reasoning of the Court

The Supreme Court’s reasoning is the cornerstone of this judgment, providing a detailed analysis of the scope of Section 37(3A) and the nature of promotional activities in the pharmaceutical sector.

1. Surtax Liability:
The Court swiftly disposed of the surtax issue, noting that it was covered by its earlier decision in Smith Kline and French (India) Ltd. & Ors. vs. CIT (1996) 219 ITR 581 (SC). Following this precedent, the Court answered the question in the negative, holding that surtax liability is not an admissible deduction in computing total income. This part of the judgment reaffirms the principle that surtax, being a tax on profits, is not an expenditure incurred for the purpose of business.

2. Physician’s Samples as Publicity and Sales Promotion:
The core of the judgment lies in the Court’s interpretation of the terms ‘advertisement, publicity, or sales promotion’ under Section 37(3A). The assessee contended that distributing samples to doctors was solely for obtaining feedback on drug efficacy and did not amount to promotion. The Supreme Court rejected this argument on multiple grounds:

– Target Audience: The Court observed that for prescription drugs, the only effective target for promotion is the medical profession. Doctors are the decision-makers who prescribe drugs to patients. Therefore, any activity aimed at influencing doctors—including distributing samples—is inherently promotional. The Court stated: “Having regard to the fact that these are prescription drugs, the target for any advertisement or publicity or sales promotion thereof could only be the doctors who would prescribe them.”

– Purpose of Distribution: The Court held that the object of distributing samples is to make doctors aware of the drug’s availability and to persuade them to prescribe it. This, the Court concluded, is “tantamount to publicity and sales promotion.” The Court dismissed the feedback argument, noting that the assessee failed to produce any evidence—such as filled questionnaires or letters from doctors—to support the claim that samples were distributed primarily for feedback. The absence of such evidence was described as “an eloquent answer” to the submission.

– Rejection of ‘Bare Minimum’ Test: The assessee relied on the Andhra Pradesh High Court’s decision in CIT vs. Ampro Food Products (1995) 215 ITR 904 (AP), which suggested that expenditure essential to the running of the business—a ‘bare minimum’—would not fall within the mischief of Section 37(3A). The Supreme Court implicitly rejected this distinction. It noted that the Karnataka High Court had already taken a broader view, and the Supreme Court endorsed that view. The Court found it difficult to separate ‘essential’ from ‘promotional’ expenditure when both serve the same purpose of creating a market for the drug. The judgment in Ampro Food Products was distinguished, and the Court favored the Karnataka High Court’s approach, which held that the three words—advertisement, publicity, and sales promotion—are not confined to distinct concepts and can overlap.

– Drugs and Magic Remedies Act: The assessee argued that classifying sample distribution as advertisement would violate the Drugs and Magic Remedies (Objectionable Advertisements) Act, 1954, which prohibits publication of advertisements for certain diseases. The Court clarified that the prohibition under that Act applies to ‘publication’ of advertisements, not to the distribution of physician’s samples. The Court stated: “We do not read the prohibition therein as applicable to physician’s samples. What is barred thereby is publication.” This distinction ensured that the tax law interpretation did not conflict with other regulatory statutes.

3. Overlap of Concepts:
The Court endorsed the Karnataka High Court’s view that the terms ‘advertisement, publicity, and sales promotion’ are not mutually exclusive. The High Court had observed: “Each of the three words… cannot always be confined to distinct and different concepts. Some aspects of one word would naturally overlap with the meaning attributed to the other word.” The Supreme Court agreed, emphasizing that the mode of achieving goodwill and market cannot be confined to limited meanings. This broad interpretation ensures that any activity designed to promote a product—directly or indirectly—falls within the ambit of Section 37(3A).

Conclusion

The Supreme Court dismissed the appeals, answering all questions in favor of the Revenue. The judgment establishes two key principles:

1. Surtax is not deductible: Following precedent, surtax liability cannot be claimed as a business expenditure under Section 37(1).
2. Physician’s samples are promotional expenditure: The distribution of free drug samples to doctors constitutes ‘publicity and sales promotion’ under Section 37(3A). This subjects such expenditure to the statutory restrictions on deductibility, including the scaling-down provisions.

The decision has far-reaching implications for the pharmaceutical industry. Companies can no longer argue that sample distribution is a non-promotional activity for feedback. The Court’s emphasis on the target audience (doctors) and the purpose (persuasion to prescribe) makes it clear that any expenditure aimed at influencing prescribers is promotional. The judgment also clarifies that the ‘bare minimum’ test from Ampro Food Products is not applicable, as it is difficult to segregate essential from promotional expenditure when both serve the same business objective. This ruling reinforces the Revenue’s ability to scrutinize and restrict deductions for promotional activities, even in regulated industries.

Frequently Asked Questions